DIOVAN HCT Rx
Generic Name and Formulations:
Valsartan, hydrochlorothiazide; 80mg/12.5mg, 160mg/12.5mg, 160mg/25mg, 320mg/12.5mg, 320mg/25mg; tabs.
Novartis Pharmaceuticals Corp
Indications for DIOVAN HCT:
Take once daily. Add-on or initial therapy and not volume-depleted: Initially 160mg/12.5mg; may increase after 1–2 weeks up to max 320mg/25mg. Replacement therapy: may be substituted for the titrated components. Maximum effects within 2–4 weeks after dose change. CrCl ≤30mL/min: not recommended.
Anuria. Sulfonamide allergy. Concomitant aliskiren in diabetics.
Fetal toxicity may develop; discontinue if pregnancy detected. Intravascular volume depletion; do not use as initial therapy. Correct salt/volume depletion before starting, or monitor closely. Hepatic or severe renal impairment. Diabetes. Gout. Asthma. Hypercalcemia. Severe CHF. Renal artery stenosis. SLE. Acute myopia. Secondary angle-closure glaucoma. Monitor electrolytes. Neonates. Pregnancy (Cat.D); monitor. Nursing mothers: not recommended.
See Contraindiactions. Monitor for hyperkalemia with K+ supplements, K+ sparing diuretics, K+ containing salt substitutes. Antagonized by cholestyramine, colestipol resins. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely, in general, avoid combined use of RAS inhibitors. Concomitant aliskiren in renal impairment (CrCl <60mL/min): not recommended. May be antagonized by, and renal toxicity potentiated by NSAIDs, including selective COX-2 inhibitors (monitor renal function periodically in elderly and/or volume-depleted). Orthostatic hypotension may be potentiated by alcohol, barbiturates, narcotics, antihypertensives. May be potentiated by inhibitors of OATP1B1 (eg, rifampin, cyclosporine) or MRP2 (eg, ritonavir). Potentiates nondepolarizing muscle relaxants. Adjust antidiabetic, antigout medications. Hyperuricemia may be potentiated by cyclosporine. Avoid lithium. May increase toxicity of digitalis, lithium. Possible symptomatic hyponatremia with carbamazepine.
Angiotensin II receptor blocker (ARB) + thiazide diuretic.
Headache, dizziness, nasopharyngitis, viral infection, fatigue, cough, diarrhea, orthostatic hypotension, electrolyte disturbances (eg, hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, increased serum cholesterol or triglycerides; rare: rhabdomyolysis.
Valsartan: Hepatic (CYP2C9); 95% protein bound. HCTZ: not metabolized.
Valsartan: fecal, renal. HCTZ: renal.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Improving Performance of Everyday Activities Is Critical in Schizophrenia
- Analysis Finds Lithium Maintenance Most Effective as Monotherapy in Bipolar Disorder
- Web-Based Intervention Targets Parental Behaviors That May Affect Adolescent Anxiety, Depression
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed
- Examining Associations Between Diabetes and Effects on Cognition
- Untreated Depression Common in Women of Childbearing Age
- Incidence of Psychiatric Disorders in Rheumatoid Arthritis
- Effect of Antidepressant Class, Dose on Pediatric Anxiety Disorders